Fig. 3
From: AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
Effect of combination treatment with ABT-263 and gefitinib on cell viability of NSCLC cells with the T790M mutation. PC-9-GR and H1975 cells were treated with different concentrations of gefitinib in the absence or presence of ABT-263 for 24h, and viability was then measured using the MTT assay. The data represent the mean ± SD of three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001